Sign in
4

Changes in Ownership

CytomX Therapeutics, Inc. Filed Acc 0001140361-18-035277

Chief Financial Officer sold 3,000 shares at $26.05 ($78,150)

  • Chief Financial Officer acquired 3,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

RAY DEBANJAN · Chief Financial Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2018-08-01 Exercise or conversion : show line 1 in the form +2,710 $1.26 $3,414 8,638 D
2018-08-01 Exercise or conversion : show line 2 in the form +290 $1.45 $420 8,928 D
2018-08-01 Sale : show line 3 in the form −3,000 $26.05 $78,150 5,928 D
Open-market sales · 3,000 sh · avg $26.05 · $78,150

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2018-08-01 Exercise or conversion : show line 4 in the form Stock Option (Right to Buy) +2,710 0 D
2018-08-01 Exercise or conversion : show line 5 in the form Stock Option (Right to Buy) +290 19,220 D
Loading xslF345X03/doc1.xml…